ReviewCurrent treatment options in oncology2008
Bone tumors in adolescents and young adults.
Review in Current treatment options in oncology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 2 syntheses or guidelines pooled it, 147 citations in OpenAlex.
- Systematic meta-analysis of genetic variants associated with osteosarcoma susceptibility.Medicine · 2018Pooled it
- Altered long non-coding RNAs predict worse outcome in osteosarcoma patients: evidence from a meta-analysis.Oncotarget · 2017Pooled it
- A Web-Based Prediction Model for Overall Survival of Elderly Patients With Malignant Bone Tumors: A Population-Based Study.Frontiers in public health · 2021Trial
- Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2015Trial
- The miR-16-1-3p passenger strand exhibits functional activity and suppresses malignant phenotypes in osteosarcoma.Frontiers in genetics · 2026Article
- Age Matters: A Systematic Review of Limb-Salvage Surgery Outcomes in Pediatric Versus Adult Osteosarcoma.Cureus · 2025Review
- Metachronous head and neck osteosarcoma in an elderly patient: A rare case report with prior verrucous carcinoma.Medicine · 2025Article
- Amputation surgery associated with shortened survival in patients with localized extremity bone sarcoma.Journal of orthopaedics · 2024Article
- The EphA2 Receptor Regulates Invasiveness and Drug Sensitivity in Canine and Human Osteosarcoma Cells.Cells · 2024Article
- Mitochondria-targeting graphene oxide nanocomposites for fluorescence imaging-guided synergistic phototherapy of drug-resistant osteosarcoma.Journal of nanobiotechnology · 2021Article
- Review
- Verteporfin disrupts multiple steps of autophagy and regulates p53 to sensitize osteosarcoma cells.Cancer cell international · 2021Article
- Double Endoprosthesis in the Management of Refractory Metastatic Primary Bone Tumors in Children and Young Adults.Advances in orthopedics · 2021Article
- MicroRNA-629-5p promotes osteosarcoma proliferation and migration by targeting caveolin 1.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2021Article
- Advances in the Management of Pediatric Sarcomas.Current oncology reports · 2020Review
- Abnormally expressed long non-coding RNAs in prognosis of Osteosarcoma: A systematic review and meta-analysis.Journal of bone oncology · 2018Article
- Codelivery of doxorubicin and JIP1 siRNA with novel EphA2-targeted PEGylated cationic nanoliposomes to overcome osteosarcoma multidrug resistance.International journal of nanomedicine · 2018Article
- miR-503 is down-regulated in osteosarcoma and suppressed MG63 proliferation and invasion by targeting VEGFA/Rictor.Cancer biomarkers : section A of Disease markers · 2018Article
- The role ofEuropean journal of nuclear medicine and molecular imaging · 2017Article
- Identification of candidate drugs for the treatment of metastatic osteosarcoma through a subpathway analysis method.Oncology letters · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementBone tumors, particularly osteosarcomas and members of the Ewing Sarcoma Family of Tumors (ESFT), are typical malignancies of adolescents and young adults. Current diagnostic and therapeutic guidelines for patients of all ages were developed in this specific age group. The aim of bone sarcoma therapy should be to cure the patient from both the primary tumor and all (micro-)metastatic deposits while maintaining as much (extremity) function and causing as few treatment-specific late effects as possible. Bone sarcoma therapy requires close multidisciplinary cooperation. Usually, it consists of induction chemotherapy, followed by local therapy of the primary tumor (and, if present, primary metastases) and further, adjuvant chemotherapy. Local treatment for osteosarcoma should be surgery whenever feasible. Surgery is also gaining importance in ESFT, which was long considered a domain of radiotherapy. Modern reconstructive techniques continue to expand the indications for limb salvage, particularly for patients who have not yet reached skeletal maturity. Treatment within the framework of prospective, multi-institutional trials should be considered standard of care not only for children, but also for affected adolescents and (young) adults. Such trials are essential in guaranteeing that all patients have access to appropriate care and that progress from biological studies can be translated into prognostic improvements without undue delay. The rarity of bone sarcomas increasingly requires trials to be multinational.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.